

Animal and Cell Models for Detection and Characterisation of Leukemic Stem Cells

PUBLICATIONS

- * Álvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, Pérez-Encinas M, Ferrer-Marín F, Barez A, Martínez-López J, Cuevas B, Mata MI, García-Gutiérrez V, Aragües P, Montesdeoca S, Burgaleta C, Caballero G, Hernández-Rivas JA, Durán MA, Gómez-Casares MT, Besses C. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. *Brit J Haematol.* 2016;172(5):786-93. Article. IF: 5.67; Q1
- * Álvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. *Haematol-Hematol J.* 2016;101(8):926-31. Article. IF: 7.702; D1
- * Calés C, Pavón L, Starowicz K, Pérez C, Bravo M, Ikawa T, Koseki H, Vidal M. Role of polycomb RYBP in maintaining the B-1-to-B-2 B-cell lineage switch in adult hematopoiesis. *Mol Cell Biol.* 2016;36(6):900-12. Article. IF: 4.398; Q1
- * Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao ZJ, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Dohner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari ML, Gale RP, Birgegard G, Xu ZF, Zhang Y, Sun XJ, Xu JQ, Zhang PH, te Boekhorst PAW, Commandeur S, Schouten H, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA. Symptomatic profiles of patients with polycythemia vera: Implications of inadequately controlled disease. *J Clin Oncol.* 2016;34(2):151-9. Article. IF: 24.008; D1
- * Gómez M, Guillem V, Pereira A, Ferrer-Marín F, Álvarez-Larrán A, Kerguelen A, Estrada N, Martínez-López J, Angona A, Amat P, Navarro B, Besses C, Hernández-Boluda JC. Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera. *Eur J Haematol.* 2016;96(3):285-90. Article. IF: 2.653; Q2
- * González-Barca E, Canales M, Salar A, Ferreiro-Martínez JJ, Ferrer-Bordes S, García-Marco JA, Sánchez-Blanco JJ, García-Frade J, Peñalver J, Bello-López JL, Sancho JM, Caballero D. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial. *Ann Hematol.* 2016;95(6):893-9. Article. IF: 3.083; Q2
- * González-Barca E, Canales MA, Salar A, Ferrer S, Domingo-Domenech E, Vidal MJ, Grande C, Bargay J, Gardella S, Oriol A, Briones J, García-Frade J, Bello JL, Sánchez-Blanco JJ, Peñalver FJ, Tomás JF, Asensio A, López A, Caballero D. Long-term follow-up of a phase II trial of six cycles of dose-dense r-CHOP-14 for first-line treatment of diffuse large B-cell lymphoma in young and elderly patients. *Acta Haematol-Basel.* 2016;136(2):76-84. Article. IF: 1.205; Q4
- * Hernández-Boluda JC, Martínez-Trillos A, García-Gutiérrez V, Ferrer-Marín F, Xicoy B, Álvarez-Larrán A, Kerguelen A, Barba P, Gómez M, Herrera JC, Correa JG, Cervantes F. Long-

term results of prednisone treatment for the anemia of myelofibrosis. *Leukemia Lymphoma*. 2016;57(1):120-4. Article. IF: 2.755; Q2

- * Martín A, Redondo AM, Dlouhy I, Salar A, González-Barca E, Canales M, Montes-Moreno S, Ocio EM, López-Guillermo A, Caballero D. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. *Brit J Haematol*. 2016;173(2):245-52. Article. IF: 5.67; Q1
- * Pérez-Chacón G, Martínez-Laperche C, Rebolleda N, Somovilla-Crespo B, Muñoz-Calleja C, Buño I, Zapata JM. Indole-3-carbinol synergizes with and restores fludarabine sensitivity in chronic lymphocytic leukemia cells irrespective of p53 activity and treatment resistances. *Clin Cancer Res*. 2016;22(1):134-45. Article. IF: 9.619; D1
- * Rebolleda N, Losada-Fernández I, Pérez-Chacón G, Castejón R, Rosado S, Morado M, Vallejo-Cremades MT, Martínez A, Vargas-Núñez JA, Pérez-Aciego P. Synergistic activity of deguelin and fludarabine in cells from chronic lymphocytic leukemia patients and in the New Zealand black murine model. *Plos One*. 2016;11(4):e0154159. Article. IF: 2.806; Q1
- * Santacatterina F, Sánchez-Cenizo L, Formentini L, Mobasher MA, Casas E, Rueda CB, Martínez-Reyes I, de Arenas CN, García-Bermúdez J, Zapata JM, Sánchez-Arago M, Satrustegui J, Valverde AM, Cuezva JM. Down-regulation of oxidative phosphorylation in the liver by expression of the ATPase inhibitory factor 1 induces a tumor-promoter metabolic state. *Oncotarget*. 2016;7(1):490-508. Article. IF: 5.168; Q1